Retina
Study provides multimodal assessment of geographic atrophy precursors
A study presented at Angiogenesis, Exudation, and Degeneration 2024 provided insights on how geographic atrophy precursors present across multiple imaging modalities.
VIDEO: Faricimab demonstrates positive real-world results at 1 year in neovascular AMD
In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Arshad M. Khanani, MD, MA, FASRS, presents 1-year real-world findings for faricimab as a treatment for neovascular age-related macular degeneration.
VIDEO: 4D-150 shows positive interim results in phase 2 trial for severe wet AMD
In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Arshad M. Khanani, MD, MA, FASRS, overviews phase 2 efficacy and safety data for 4D-150 for the treatment of neovascular age-related macular degeneration.
VIDEO: Post hoc analyses support angiopoietin-2 inhibition in retinal disease treatment
In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Rishi P. Singh, MD, overviews post hoc analyses supporting angiopoietin-2 inhibition for treating retinal diseases.
VIDEO: Phase 2 study compares two preparations of ABBV-RGX-314
In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, David A. Eichenbaum, MD, discusses data on ABBV-RGX-314 for neovascular age-related macular degeneration.
VIDEO: Faricimab dosing interval may extend up to 20 weeks in wet AMD, DME
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Michael A. Singer, MD, presents data on dosing intervals for faricimab as a treatment for wet age-related macular degeneration and diabetic macular edema.
Pegcetacoplan for geographic atrophy receives negative opinion from European committee
The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on a marketing authorization application for pegcetacoplan, according to an Apellis Pharmaceuticals press release.
VIDEO: Fluocinolone acetonide implant shows promise for treatment of noninfectious uveitis
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Danny A. Mammo, MD, presents data investigating the 0.18 mg fluocinolone acetonide implant for the treatment of noninfectious uveitis in the posterior segment.
VIDEO: Gene therapy has potential to reduce injection burden
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, David A. Eichenbaum, MD, discusses the potential for gene therapy to reduce the intravitreal injection treatment burden in retinal disease.
Decision-making for geographic atrophy treatment multifactorial
WAILEA, Hawaii — When making treatment decisions for geographic atrophy, atrophy geometry, lesion size and focality are some of the features that must be considered, according to a speaker here.